drugset / Trial / NCT06419673
Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer
Phase 2
Active not recruiting
240 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is a prospective, multicenter, randomized, open controlled clinical trial aimed at evaluating the effectiveness and safety of serplulimab plus chemoradiotherapy in FIGO 2018 stage III or IVA cervical squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma patients who have not received prior treatment.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2025-05-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |